<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02546297</url>
  </required_header>
  <id_info>
    <org_study_id>20150717</org_study_id>
    <nct_id>NCT02546297</nct_id>
  </id_info>
  <brief_title>Comparisons of Inhaled LAMA or ICS+LABA for COPD With Bronchiectasis</brief_title>
  <official_title>The Comparisons of the Efficacy and Safety of Inhaled LAMA or ICS+LABA for Patients in COPD C Group With Bronchiectasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Pulmonary Hospital, Shanghai, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine which treatment is more effective and safer for the
      patients in COPD C group with bronchiectasis.The research results will help guide physicians
      to select appropriate individualized treatment and hopefully provide some evidence-based
      medicine proofs for revising guide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The diagnosis and treatment of COPD and bronchiectasis together seems to be more complicated
      than the diagnosis and treatment of either condition alone. According to the GOLD，there are
      two treatments for patients with COPD in group C: ICS combined with LABA or LAMA alone.
      However, it has not yet been demonstrated about which method is more effective for the
      patients with COPD in group C and bronchiectasis.

      This study is designed as a prospective, randomized, case-control trial. Patients are divided
      into two groups, one group inhaled with ICS and LABA (Symbicort), another group inhaled with
      LAMA (Tiotropium Bromide).The course of treatment is 12 months. The treatment will be
      exchanged in the 7th month.

      The investigators will also assess other relevant outcomes, including the quality of life
      (QOL) score, pulmonary function test and the incidence of adverse event.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute exacerbation</measure>
    <time_frame>12 months</time_frame>
    <description>The times of acute exacerbation during the trial.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>All of the adverse events occurred in the processing of the trial,especially the prevalence of pneumonia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function tests</measure>
    <time_frame>12 months</time_frame>
    <description>FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function tests</measure>
    <time_frame>12 months</time_frame>
    <description>FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function tests</measure>
    <time_frame>12 months</time_frame>
    <description>FEV1/FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>SGRQ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>LCQ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>CAT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>mMRC</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>COPD</condition>
  <condition>Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>ICS/LABA Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Symbicort，Inhalation，Individualized medication，six months，The treatment will be exchanged in the 7th month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LAMA Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiotropium Bromide，Inhalation,Individualized medication，six months，The treatment will be exchanged in the 7th month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symbicort</intervention_name>
    <description>drug are used for six months，and then exchanged in the 7th month</description>
    <arm_group_label>ICS/LABA Group</arm_group_label>
    <other_name>Budesonide/Fomoterol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium Bromide</intervention_name>
    <description>drug are used for six months，and then exchanged in the 7th month</description>
    <arm_group_label>LAMA Group</arm_group_label>
    <other_name>Spiriva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients are suitable for inclusion in the study when they are 18 years or older
             diagnosed with COPD C group and bronchiectasis.

        Exclusion Criteria:

          -  active tuberculosis

          -  severe respiratory disease (such as Lung cancer, ARDS, pulmonary encephalopathy,
             respiratory failure)

          -  uncontrollable diabetes

          -  hypersensitivity to any components of ICS/LABA or LAMA.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin-Fu Xu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Pulmonary Hospital , Tongji University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin-Fu Xu</last_name>
    <phone>+86 13321922898</phone>
    <email>13321922898@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ke Fei, MD,PhD</last_name>
      <phone>+86 21 65115006</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Oba Y, Lone NA. Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2014 May 12;9:469-79. doi: 10.2147/COPD.S48492. eCollection 2014. Review.</citation>
    <PMID>24872685</PMID>
  </results_reference>
  <results_reference>
    <citation>Kew KM, Dias S, Cates CJ. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev. 2014 Mar 26;(3):CD010844. doi: 10.1002/14651858.CD010844.pub2. Review.</citation>
    <PMID>24671923</PMID>
  </results_reference>
  <results_reference>
    <citation>Manoharan A, Short PM, Anderson WJ, Lipworth BJ. Impact of long-acting bronchodilators and exposure to inhaled corticosteroids on mortality in COPD: a real-life retrospective cohort study. Lung. 2014 Oct;192(5):649-52. doi: 10.1007/s00408-014-9611-8. Epub 2014 Jun 22.</citation>
    <PMID>24952426</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2015</study_first_submitted>
  <study_first_submitted_qc>September 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2015</study_first_posted>
  <last_update_submitted>April 20, 2016</last_update_submitted>
  <last_update_submitted_qc>April 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Pulmonary Hospital, Shanghai, China</investigator_affiliation>
    <investigator_full_name>Jin-Fu Xu</investigator_full_name>
    <investigator_title>Department of Respiratory Medicine</investigator_title>
  </responsible_party>
  <keyword>LAMA,ICS+LABA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

